CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Non-GAAP Tax Rate: 19.8% for Q3 2024. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported a 12% year-over-year revenue growth for Q3 2024, reaching $2.77 billion. The company increased its full-year ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.25% to $493.64 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2 ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.36% higher to $472.80 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) released a profit for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...